Trial Profile
Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary) ; Bicalutamide; Goserelin; Hydrocortisone; Ketoconazole
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms TAPS
- Sponsors GlaxoSmithKline
- 13 Feb 2021 Results of pooled analysis of post-RP outcomes from four clinical trials (NCT00298155; NCT00924469; NCT01547299; NCT02268175) presented at the 2021 Genitourinary Cancers Symposium
- 26 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Dec 2013 Results published in the Journal of Clinical Oncology.